Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941441 · ClinicalTrials.gov registry record · Phase 3
PAH Exercise Study
A Phase 3 study of Pulmonary Arterial Hypertension PAH and Exercise Therapy, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06941441: Recruiting Phase 3 study of Pulmonary Arterial Hypertension PAH and Exercise Therapy, sponsored by University of Washington.
NCT06941441 is a Phase 3 study of Pulmonary Arterial Hypertension PAH and Exercise Therapy that is actively recruiting participants, run by University of Washington. The registered enrollment target is 10 participants, below the 46-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941441, a Phase 3 study of Pulmonary Arterial Hypertension PAH and Exercise Therapy, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.
Conditions Studied
Interventions
- OTHER Home exercise program
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What NCT06941441 shows while recruiting
NCT06941441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 46-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 1 intervention - of which Home exercise program is the first listed.
NCT06941441 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06941441 about?
NCT06941441 is a clinical study titled "PAH Exercise Study". Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn...
What is the current status of trial NCT06941441?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2025-04-15. Estimated completion is 2026-09-30.
What conditions does trial NCT06941441 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH, Exercise Therapy.
What interventions are being tested in trial NCT06941441?
The interventions under investigation include: Home exercise program (OTHER).
Who is sponsoring clinical trial NCT06941441?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941441 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension PAH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
RECRUITING · NA
-
Study of Intravenous ZMA001 in Healthy Subjects
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RECRUITING · Phase 2
-
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI